Zhang Financial LLC Has $3.88 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Zhang Financial LLC raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 4.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,480 shares of the medical research company’s stock after purchasing an additional 617 shares during the quarter. Zhang Financial LLC’s holdings in Amgen were worth $3,883,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. Beaumont Financial Advisors LLC boosted its holdings in shares of Amgen by 1.0% in the 4th quarter. Beaumont Financial Advisors LLC now owns 4,757 shares of the medical research company’s stock worth $1,370,000 after acquiring an additional 48 shares in the last quarter. Davidson Trust Co. boosted its holdings in shares of Amgen by 11.3% in the 4th quarter. Davidson Trust Co. now owns 1,928 shares of the medical research company’s stock worth $555,000 after acquiring an additional 195 shares in the last quarter. HTLF Bank acquired a new position in shares of Amgen in the 4th quarter worth approximately $8,771,000. Fidelis Capital Partners LLC raised its position in Amgen by 26.7% in the 4th quarter. Fidelis Capital Partners LLC now owns 3,569 shares of the medical research company’s stock worth $1,028,000 after purchasing an additional 753 shares during the last quarter. Finally, Obermeyer Wood Investment Counsel Lllp raised its position in Amgen by 4.3% in the 4th quarter. Obermeyer Wood Investment Counsel Lllp now owns 4,087 shares of the medical research company’s stock worth $1,177,000 after purchasing an additional 169 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. The Goldman Sachs Group boosted their price objective on shares of Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Truist Financial reiterated a “buy” rating and set a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. Raymond James started coverage on shares of Amgen in a research report on Thursday, March 28th. They set a “market perform” rating for the company. UBS Group decreased their price target on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a report on Wednesday. Finally, Oppenheimer restated an “outperform” rating and set a $350.00 price objective on shares of Amgen in a research note on Thursday, February 1st. Ten equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, Amgen currently has an average rating of “Moderate Buy” and a consensus target price of $296.95.

Amgen Trading Up 1.8 %

Shares of Amgen stock traded up $4.66 during trading on Friday, hitting $267.41. The company’s stock had a trading volume of 1,312,157 shares, compared to its average volume of 2,831,060. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $329.72. The stock has a market cap of $143.31 billion, a price-to-earnings ratio of 21.22, a price-to-earnings-growth ratio of 2.46 and a beta of 0.58. The stock has a 50-day moving average price of $277.34 and a two-hundred day moving average price of $281.24.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping the consensus estimate of $4.66 by $0.05. The company had revenue of $8.20 billion for the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. Amgen’s revenue for the quarter was up 19.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.09 earnings per share. Equities research analysts anticipate that Amgen Inc. will post 19.45 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a dividend yield of 3.37%. Amgen’s dividend payout ratio is currently 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.